AEAlexander Epifanov

Alexander Epifanov

*This is an algorithmically generated author record based on publicly available information.

Alexander Epifanov has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Study of the combined use of the drug bovhyaluronidase azoximer and extracorporeal shock wave therapy in patients with chronic prostatitis

    by M. V. Epifanova, А. А. Kostin, E. V. Slavkina, S. A. Artemenko, А. А. Epifanov

    Introduction: the problem of treating chronic prostatitis (CP), due to its negative impact on quality of life, requires the search for effective methods of treatment. The study objective: to evaluate the efficacy and safety of the combined use of extracorporeal shock wave therapy (ESWT) and the drug bovhyaluronidase azoximer in the treatment of patients with CP. Materials and methods: the research included 70 men (mean age 44.8 ± 7.3 years) with CP, fibrotic changes and/ or calcinates in the prostate according to transrectal ultrasound (TRUS). According to the NIDDK/NIH classification, рatients with category II CP were divided into group 1 ( n = 20) — ESWT, 3-As-therapy, while patients with category IIIA and IIIB CP were randomized into group 2 ( n = 20) — ESWT monotherapy, and group 3 ( n = 30) — ESWT, the drug bovhyaluronidase azoximer. All participants underwent ESWT sessions targeting the perineum twice a week for 6 weeks. Assessments were conducted at baseline, weeks 7, 10, and 18, and included NIH-CPSI, IPSS, IIEF-5, VAS, uroflowmetry, TRUS, prostate secretion microscopy/sperm analysis, culture of prostate secretion/sperm, total PSA levels for men over 50 years. Results: by week 18, the intragroup results showed improvement in laboratory parameters, erectile function, relief from pain and dysuria, reduction in prostate volume, calcinates and fibrosis size ( p < 0.05). Analysis of variance between groups showed significant differences in NIH-CPSI, IPSS, VAS, Qmax, Qave, prostate volume, calcinates and fibrosis size ( p < 0.05). At weeks 7, 10, and 18, group 3 demonstrated significant ( p < 0.05) regression of symptoms for the parameters studied compared to groups 1 and 2. Conclusion: the presented treatment methods effectively alleviate CP symptoms and improve patients’ quality of life. The combination of ESWT and bovhyaluronidase azoximer shows significantly greater efficacy compared to ESWT monotherapy and the combination of ESWT with 3-As-therapy.

  • Long-term effect of extracorporeal shock wave therapy in combination with bovhyaluronidase azoximer in chronic prostatitis / chronic pelvic pain syndrome (clinical example)

    by M. V. Epifanova, А. А. Kostin, E. V. Slavkina, S. A. Artemenko, M. A. Vekilyan, А. А. Epifanov

    Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) remains a relevant medical issue in the modern world due to the lack of effective treatment options. The condition significantly impairs quality of life by negatively affecting sexual, reproductive, and psycho-emotional health. In recent years, increasing attention has been paid to the role of prostatic fibrosis in disrupting glandular function, contributing to urinary disorders, and reducing male fertility. Efforts are underway to identify optimal therapeutic strategies. This article presents a clinical case of a patient with pronounced prostatic fibrosis associated with CP/CPPS category IIIB. The treatment included a combination of extracorporeal shock wave therapy and the enzyme-based drug bovhyaluronidase azoximer. Following the treatment course, improvements were observed in clinical and laboratory parameters, as well as in the findings of instrumental diagnostic methods.

  • Recovery of erectile function in patients after radical prostatectomy using platelet rich plasma and extracorporeal shock wave therapy: a controlled study

    by M. V. Epifanova, S. A. Artemenko, А. А. Kostin, А. А. Epifanov, E. V. Slavkina

    Background. Prostate cancer (PCa) remains one of the leading oncological causes of morbidity in men. Despite advances in modern surgical techniques, including nerve-sparing radical prostatectomy (RP), erectile dysfunction (ED) remains a frequent and significant complication that substantially affects patients’ quality of life. Currently available rehabilitation methods have limitations in terms of effectiveness or accessibility. Aim. To evaluate the efficacy and safety of the combined use of autologous plasma enriched with platelet-rich plasma (PRP) and extracorporeal shockwave therapy (ESWT) in the restoration of erectile function in patients with erectile dysfunction following nerve-sparing radical prostatectomy. Materials and Methods. A prospective controlled study included 46 patients who had undergone unilateral or bilateral nerve-sparing robot-assisted RP. Group 1 received PRP injections combined with ESWT sessions. Group 2 (control) received tadalafil therapy. Assessments were conducted at baseline and on the 60th day of treatment. Validated scales were used: IIEF-5, SEP, EHS, IPSS, QOL, ICIQ-SF, GAQ, as well as penile vascular pharmacodopplerography (PDG), uroflowmetry (UFM), and total testosterone levels. Results. The combination therapy group (PRP + ESWT) demonstrated a significant improvement in erectile function indicators: IIEF-5 (p < 0.001), SEP (p < 0.001), EHS (p < 0.001), improved hemodynamics according to PDG (PSV and RI, p < 0.001), resolution of urinary incontinence symptoms per ICIQ-SF (p < 0.001), and improved urination according to UFM data (p < 0.001). No significant improvement in erectile function was recorded in the control group. No differences in safety profiles were observed between the groups. Conclusion. The combination of PRP and ESWT showed high clinical efficacy and safety in patients with postprostatectomy erectile dysfunction. This method warrants further investigation and may be recommended as an effective penile rehabilitation strategy following RP.

  • Combined physical and enzymatic therapy for chronic prostatitis and chronic pelvic pain syndrome.

    by M.V. Epifanova, Russia Moscow, A.A. Kostin, E.V. Slavkina, S.A. Artemenko, A.а. Epifanov

    Introduction. Chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS) are the most prevalent urological disorders, affecting up to 14% of men and significantly reducing quality of life. The limited effectiveness of conventional treatment regimens increases interest in physiotherapeutic approaches, including extracorporeal shock wave therapy (ESWT), and in the use of enzymatic preparations. Objective. To evaluate the efficacy of ESWT, bovhyaluronidase azoximer (BA) as part of a treatment regimen in patients with Category II CP and Categories IIIA–IIIB CPPS. Materials and Methods. The randomized, open-label, placebo-uncontrolled study included 116 men aged 20–65 years (mean 45,5±9,5; disease duration 20,8±7,7 months). There were 3 study groups. Group 1 (n = 37) received ESWT + «3-As» therapy (antibiotic, NSAID, α-blocker); Group 2 (n = 38): ESWT monotherapy; Group 3 (n = 41): ESWT + BA (3000 IU). Efficacy was assessed at baseline and at weeks 7, 10, 18, 30, and 54 using the NIH-CPSI, IPSS, IIEF-5, and VAS scores, uroflowmetry, transrectal ultrasound with elastography and Doppler, and laboratory tests. Results. All patients completed treatment without adverse effects. Improvement at week 7 was most pronounced in Group 1 according to NIHCPSI, IPSS, VAS, and uroflowmetry (p < 0.05). By weeks 10–54, positive dynamics were observed in all groups, with the most stable and pronounced effect in Group 3, where ESWT combined with BA reduced the number and size of calcifications and fibrotic areas, increased normal elasticity regions, and improved prostatic blood flow. Intergroup analysis confirmed the superiority of Groups 1 and 3 over Group 2, with no significant differences between Groups 1 and 3. In patients with non-inflammatory CP/CPPS (IIIB), a significant improvement in erectile function (IIEF-5) was also recorded. Conclusions. ESWT, particularly when combined with BA, provides a significant reduction in CP/CPPS symptoms, improves uroflowmetry and ultrasound parameters of the prostate, and demonstrates superiority over standard therapy.

  • A Randomized Controlled Clinical Trial on the Study of Autologous Plasma Enriched with Platelet Growth Factors and Extracorporeal Shock Wave Therapy in the Treatment of Peyronie’s Disease

    by M.V. Epifanova, Moscow 6 Miklukho-Maklaya St., А.а. Kostin, S.A. Artemenko, А.а. Epifanov, Moscow 127006 Fsbei He “Rosunimed” Of Moh Of Russia; 4 Dolgorukovskaya St.

    Background: The results of conservative methods of treating Peyronie’s disease (PD) do not exceed the placebo effect, and surgical treatment does not always lead to satisfactory outcomes. Aim: to evaluate the safety and effectiveness of using platelet rich plasma (PRP) and extracorporeal shock wave therapy (ESWT) in patients with PD. Materials and Methods: The study included 40 patients with PD, randomly assigned into two equal groups. Group 1 received ESWT (Dornier Medtech GmbH, Germany, D82234 Wessling, 62 Argelsrieder Feld, 7, Germany (FSZ 2011/09554) on the penis, targeting the fibrotic areas and calcifications twice weekly for 6 weeks. Group 2 underwent 2 visits per week for 6 weeks. Visit 1 involved PRP injections and ESWT on the penis, fibrotic areas, and calcifications. Visit 2 included only ESWT on the same areas. Outcomes were assessed on days 0 and 60 (median (IQR%)) using the Peyronie’s Disease Questionnaire (PDQ), Visual Analog Scale (VAS) during sexual intercourse and erection, penile curvature angle, plaque size, and calcifications based on penile ultrasound. Results: the treatment was well tolerated by all patients. No side effects were recorded. In group 2, one patient experienced disease progression, developing a «hourglass» deformity of the penis. Both groups showed significant reductions in pain and PD symptoms, as measured by VAS during erection (p = 0.001028, p < 0.001) and VAS during sexual intercourse (p = 0.01604, p < 0.001), as well as improvement in PDQ scores (p < 0.001, p < 0.001). The penile curvature angle also significantly decreased in both groups (p = 0.02364, p = 0.007346). While the size and number of calcifications decreased slightly (p > 0.05), the fibrotic plaque area showed significant regression in both groups (p = 0.001929, p = 0.003188). Post-treatment analysis showed a significant difference in plaque size reduction, VAS during erection, and during sexual intercourse in favor of patients who received APGF in combination with ESWT (p < 0.05). Conclusion: PRP and ESWT may represent a promising conservative strategy for treating PD. Combined therapy of APGF and ESWT is more effective in reducing pain and fibrotic plaque size in the penis compared to ESWT alone. Keywords: Peyronie’s disease, platelet rich plasma, extracorporeal shock wave therapy, growth factors, regenerative medicine, erectile dysfunction.

  • Possibilities of comprehensive rehabilitation in combination with vitamin and mineral preparations for patients who have undergone hospitalization COVID-19 form

    by A. O. Romanov, A. V. Epifanov, A. N. Arkhangelskaya, M. V. Ivkina, O. V. Levchenko, I. I. Glazkova

    Relevance. Rehabilitation of patients who have suffered severe and moderate COVID-19 is an urgent task of modern medicine. Today, the most important are rehabilitation measures for people who have undergone hospitalization. The goal is to study. The possibility of comprehensive rehabilitation of patients who have suffered hospital-acquired COVID-19, incl. using vitamin and mineral preparations. Materials and methods. A total of 195 consecutively recruited patients were examined. There were 2 groups of patients: with moderate severity (111 (56.92 %)) and severe severity (84 (43.0 %)). After discharge from the hospital, patients were randomly divided into 4 groups: Group A — 47 patients who received a rehabilitation complex, including therapeutic physical education (therapeutic and breathing exercises), physiotherapeutic treatment (inhalation and respiratory support) in accordance with the recommendations of the Ministry of Health Russian Federation, drug therapy in accordance with the recommendations of the Ministry of Health of the Russian Federation (anticoagulant therapy, if indicated — HMG-CoA reductase inhibitors, oral hypoglycemic therapy, ACE inhibitors and sartans); Group B — 49 patients who, in addition to the above methods, received vitamin preparations (vitamin D 1500 IU/day and vitamin C 30 mg/day); Group B — 48 patients who, in addition to the above methods, received mineral preparations (zinc 15 mg/day and selenium 70 mcg/day); Group D — 51 patients who, in addition to the above methods, received vitamins and mineral preparations in the previously indicated doses for groups B and C. The dynamics of mineral metabolism parameters were assessed. Results. During the examination of patients upon discharge from the hospital, a change in the content of macroelements was established: an increase in the level of potassium, sodium, sulfur and a decrease in calcium, as well as microelements: an increase in antimony and barium and a decrease in zinc, selenium and silicon. The most pronounced positive effect in terms of increasing the levels of essential macro- and microelements in the body (zinc, selenium and iron) in patients who had hospitalized COVID-19 was observed when using rehabilitation complexes in combination with vitamin and mineral preparations.

  • Open Access

    Is platelet-rich plasma and extracorporeal shock wave therapy a new frontier in treating patients with erectile dysfunction?

    by M. V. Epifanova, А. А. Kostin, S. A. Artemenko, А. А. Epifanov

    Background. Existing methods for treating erectile dysfunction (ED) do not always provide the necessary therapeutic effect and/or may not be recommended for certain patients. Aim. Evaluate the effectiveness of correcting erectile dysfunction using platelet-rich plasma (PRP) and extracorporeal shock wave therapy (ESWT). Material and methods . 100 men were randomly assigned to 3 groups. Group 1 (n=20) received ESWT treatment on the penis twice a week for 6 weeks. Group 2 (n=40) and Group 3 (n=40) had two visits per week for 6 weeks, involving both ESWT and PRP injections into the penis. In Group 2, PRP activation was performed using ESWT, while in Group 3, it was done using a 10% solution of CaCl2. Patients were evaluated at 0 and 60 days of the study, assessing IIEF-5, SEP, EHS, GAQ, blood testosterone levels, and penile Doppler ultrasound with PGE1. Results. In group 1 IIEF-5 improved from 14.5 (10.5-17) to 19.5 (15.5-21) (рConclusion. All treatment methods were well-tolerated by all patients. The study results indicate a positive trend in improving erectile function and increasing total testosterone levels in the blood. When comparing groups, combination therapy significantly improves erectile function according to SEP, EHS, and penile Doppler ultrasound assessments. ESWT can be suggested as an activator for PRP.

  • Open Access

    Technologies of regenerative medicine as a method of treatment of male infertility: literature review

    by M. V. Epifanova, А. А. Kostin, А. А. Epifanov, K. A. Kirillova

    The problem of infertility has recently become quite widespread all over the world, having a negative impact on couples themselves and society as a whole. The male factor of infertility accounts for about 50% of cases, in this regard, a large number of studies conducted are aimed at finding new methods of treating this disease. However, the accepted modern methods of treatment, including assisted reproductive technologies, are currently not effective enough. Recently, much attention has been devoted to the use of regenerative medicine technologies in the treatment of diseases of the reproductive system of men and women due to its significant potential. This review presents existing experimental and clinical studies that studied the effect, safety and efficacy of stem cells of various kinds of origin, induced pluripotent stem cells, exosomes, spermatogonial stem cells, platelet rich plasma in the treatment of various types of male infertility.


  • Open Access

    Safety and potential effectiveness of platelet-rich plasma and extracorporeal shock wave therapy in the treatment of erectile dysfunction after nerve-sparing radical prostatectomy in patients: pilot study

    by M. V. Epifanova, S. A. Artemenko, A. A. Kostin, A. A. Epifanov, K. A. Kirillova

    Background . Prostate cancer is the most common type of cancer in men. Radical prostatectomy (RPE), including nerve-sparing, often leads to erectile dysfunction and a significant decrease in the quality of life. The available treatments are limited in effectiveness and/or are not suitable for patients. Aim. The aim of the study was to evaluate the safety and effectiveness of platelet-rich plasma (PRP) and extracorporeal shock wave therapy (ESWT) in the treatment of erectile dysfunction in patients after nerve-sparing RPE. Materials and methods . 14 men were included in the study after unilateral or bilateral nerve-sparing RPE more than 3 months ago. The total prostate-specific antigen in all patients was less than 0.2 ng/ml 3 months or more after surgery. Age – 57.8 ± 6.2 (49–72) years, duration of erectile dysfunction – 7.6 ± 3.9 (3–16) months. Two visits per week were out for 6 weeks: in visit 1, the ESWT (Dornier Aries) was performed on penis and injections of PRP into the penis, the muscles involved in the erection were activated at the end of the session by ESWT, in visit 2, ESWT on penis. The examinations were performed on the 0 and 60 days of the study: International Index of Erectile Function (IIEF-5), Sexual Encounter Profile (SEP), Erection Hardness Score (EHS), Global Assessment Questionnaire (GAQ), International Prostate Symptom Score (IPSS), Quality of Life (QoL), total blood testosterone, to penile duplex Doppler ultrasonography (PDDU) with prostaglandin E1 analog. Inclusion criteria were absence of metastases to distant organs and lymph nodes; stage no more than T3b; IIEF-5 less than 21 points after RPE; PSV less than 30 cm/s and/or RI less than 0.8 according to the PDDU after RPE; the presence of erections before RPE. Results. Treatment was tolerated satisfactorily for all patients. Significant improvement of erectile function was noted according to IIEF-5 (p Conclusion. There are positive effects in relation to a significant improvement in erectile function in all patients according to validated questionnaires and PDDU. The proposed treatment is a promising method of restoring patient data. The study continues on a larger sample of patients.


  • Open Access

    Genetic predictors of Peyronie’s disease: review

    by M. V. Epifanova, A. A. Kostin, E. V. Gameeva, K. R. Ikonova, S. A. Artemenko, A. A. Epifanov, V. B. Chernykh

    Peyronie’s disease (PD) is a benign fibrous lesion in the albuginea of the penis that can occur in men of various ages. Despite the fact that epidemiological and pathophysiological data on PD are contradictory, there are a number of comorbidities that suggest a genetic predisposition to this pathology. Genetic and molecular studies of PD are insufficient and their results are often contradictory. This literature review will consider the most studied and potential genetic predictors of PD, namely: transforming growth factor β1, myostatin, matrix metalloproteinases, Wnt signaling pathway, microRNAs (MiR-29b), major histocompatibility complex proteins (human leukocyte antigen). Expanding the possibilities of early diagnosis of the disease will increase the effectiveness of the treatment.